nivolumab
Start here
The 5-year analysis of the phase 3 RELATIVITY-047 trial showed statistically significant differences in progression-free survival, overall survival, and melanoma-specific survival between relatlimab plus nivolumab and nivolumab alone in advanced melanoma.
Excerpted from nature.com
Coverage timeline
Follow the coverage to see the different angles.
- nature.comRelatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial
The 5-year analysis of the phase 3 RELATIVITY-047 trial showed statistically significant differences in progression-free survival, overall survival, and melanoma-specific survival between relatlimab plus nivolumab and nivolumab alone in advanced melanoma.
- x.com#ESMO26
- LancetDisease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial.
At the data cutoff of June 19, 2026, the single-arm, multicentre phase 2 NICHE-2 trial showed that neoadjuvant ipilimumab plus nivolumab in locally advanced mismatch repair-deficient colon cancer achieved a 3-year disease-free survival of 100% (97.5% CI 100-100) and an exploratory 5-year overall survival of 100% (95% CI 100-100).
- medicalxpress.comNo disease recurrences after short course of neoadjuvant immunotherapy, according to follow-up
Long-term follow-up of NICHE-2 shows no recurrences among the 111 patients in the primary efficacy population with dMMR colon cancer treated with neoadjuvant nivolumab plus ipilimumab. In the single-arm, multicenter phase 2 study, patients received two cycles over about 4 weeks before surgery; pathological response was 98% and pathological complete response 68%. With median postoperative follow-up of 58.7 months, 3-year disease-free survival and estimated 5-year overall survival were both 100%, and all patients were alive at last follow-up.
- thelancet.comPick[Articles] Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
The single-arm, multicentre, phase 2 NICHE-2 trial in the Netherlands showed that patients with locally advanced dMMR colon cancer who received ipilimumab and nivolumab before surgery had 3-year disease-free survival and 5-year overall survival of 100%. The authors consider that this neoadjuvant combination may become a standard treatment option for locally advanced dMMR colon cancer.
- Mol Med RepNavigating the landscape of targeted therapies for renal cell carcinoma in the era of precision medicine (Review)
This review integrates the molecular mechanisms of renal cell carcinoma (RCC) with phase III clinical evidence, systematically evaluating the therapeutic landscape of VEGF-TKIs, mTOR inhibitors, immune checkpoint inhibitors as monotherapies, and combination regimens including nivolumab plus ipilimumab, pembrolizumab plus axitinib, and lenvatinib plus pembrolizumab.
- CancerPerioperative immunotherapy in head and neck squamous cell carcinoma
Perioperative immunotherapy in resectable head and neck squamous cell carcinoma (HNSCC) has reached a key phase III milestone: adjuvant nivolumab improved DFS in patients with pathologic high-risk resected disease, and perioperative pembrolizumab significantly prolonged EFS in locally advanced disease. Biological evidence supports integrating immunotherapy into perioperative strategies to improve long-term outcomes.
- doi.orgPerioperative immunotherapy in head and neck squamous cell carcinoma
Perioperative immunotherapy for resectable head and neck squamous cell carcinoma (HNSCC) has reached a turning point, with two phase III trials reporting positive results: adjuvant nivolumab improved disease-free survival (DFS) in HNSCC with pathologic high-risk features after resection, and perioperative pembrolizumab significantly prolonged event-free survival (EFS) in resectable locally advanced HNSCC. These data are driving a shift from conventional adjuvant frameworks toward integrated perioperative immunotherapy strategies, with the potential to improve long-term patient outcomes.
- medicalxpress.comPickScientists identify clues to making immunotherapy more effective against glioblastoma
Neoadjuvant nivolumab plus ipilimumab extended median survival to about 13.5 months versus roughly nine months with nivolumab alone in a phase 2 trial of 63 patients with recurrent glioblastoma. Five patients, about 15% of the combination group, became long-term survivors, with none on nivolumab alone. Tumor T-cell density independently predicted overall survival, and early pseudoprogression on MRI correlated with longer survival, pointing to biomarkers for patient selection.
Heat trend for this story
Heat now 105·Peak in the comparable set 140 (Oct 25 02:00)·Change over 24h in the comparable set +9%·Participants now 25
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.